# A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Source: https://onco.cc/trials/nct05296798/  
OnCo record `nct05296798` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Giredestrant and Docetaxel in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) is a phase 3 interventional study registered as NCT05296798 by Hoffmann-La Roche, with 922 participants enrolled, started 2022-07-18 and due to reach its primary completion in 2027-10-31. Interventions recorded: Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist and Optional Endocrine Therapy of Investigator's Choice.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05296798
- Phase: 3
- Setting: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
- Sponsor: Hoffmann-La Roche
- Enrolled: 922

## Sources

- ClinicalTrials.gov NCT05296798: https://clinicaltrials.gov/study/NCT05296798

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Giredestrant](https://onco.cc/drugs/giredestrant/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct05296798.json